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Abstract:  Hypertension is one of the major risk factors for cardiovascular disease. 
Although various drugs for its treatment have been synthesized, the occurring side effects 
have generated the need for natural interventions for the treatment and prevention of 
hypertension. Dietary intervention such as the administration of prebiotics has been seen as 
a highly acceptable approach. Prebiotics are indigestible food ingredients that bypass 
digestion and reach the lower gut as substrates for indigenous microflora. Most of the 
prebiotics used as food adjuncts, such as inulin, fructooligosaccharides, dietary fiber and 
gums, are derived from plants. Experimental evidence from recent studies has suggested 
that prebiotics are capable of reducing and preventing hypertension. This paper will discuss 
some of the mechanisms involved, the evidence generated from both in-vitro experiments 
and in-vivo trials and some controversial findings that are raised. 
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1. Introduction 
 
Hypertension is defined as an elevation in blood pressure, where a blood pressure exceeding   
140/90 mm Hg is considered as elevated, and a lower threshold of 130/80 mm Hg was applied for 
individuals with diabetes or
 chronic kidney disease [1].
 Hypertension has been identified as one of the 
risk factors for the emergence of cardiovascular diseases. Past hypertension intervention trials have 
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revealed that the risk treatment of hypertension could reduce the risks of stroke by 42% and a 14% 
reduction
 in coronary heart disease [2]. In order to treat hypertension, synthetic drugs have been 
developed by the pharmaceutical industry. However, such drugs have been reported to produce side 
effects including insomnia, angioedema, cough and fetal abnormalities [3]. Considering the side 
effects of synthetic drugs, dietary treatment has gained much attention lately as the alternative 
antihypertensive approach. Dietary components including prebiotics are seen as better alternatives than 
drug therapy to treat hypertension considering that prebiotics has a long history of safe use and has 
been a natural component present in our foods.  
Prebiotics are non-digestible food ingredients that can escape digestion under the harsh conditions 
of the upper gastrointestinal tract and reach the lower gut as substrates for the fermentation by 
selective indigenous gut microflora. Most of the prebiotics studied are plant derivatives such as 
fructooligosaccharides (FOS), inulin and fibers. FOS contains 2 to 10 fructose units linked by 
glycosidic bonds, while inulin is a fructose polymer with β-(2-1) glycosidic
 linkages with chains of  
3 to 60 units. Both FOS and inulin are found abundantly in chicory and artichokes. The major 
component of chicory root
 is inulin. Inulin belongs to the fructan family, and occurs naturally as 
important storage carbohydrates. Other than chicory, fructans are also found present in artichokes, 
salsify, asparagus
 and onions [4]. Plant fibers are also found to exert prebiotic properties, health 
enhancing effects and strongly influence the metabolism of carbohydrates and lipids, which are 
directly associated with the increased risks of hypertension. Prebiotics from various plant sources have 
very different chemical structures, physicochemical properties, and physical states. The extraction of 
prebiotics, especially of plant fiber origin often relies on water solubility or extractability, where plant 
fibers can be divided into soluble fibers and insoluble fibers [5]. Both soluble and insoluble fibers have 
been found to exert hypocholesterolemic and hypoglycemic effects that could subsequently lead to an 
antihypertensive effect. This paper will discuss some of the antihypertensive mechanisms that have 
been documents. 
This paper will also discuss some of the experimental evidence on the antihypertensive properties 
of plant derived prebiotics, with emphasis on their hypocholesterolemic and hypoglycemia effects. 
However, controversies have arisen where some studies showed promising results while others 
exhibited insignificant findings. Thus, this paper will also highlight some of these controversies.  
 
2. Antihypertensive Mechanisms of Prebiotics 
 
Various mechanisms have been postulated to explain the ability of prebiotics to reduce the risk of 
hypertension. One of the possible mechanisms is via the lowering of blood lipid and cholesterol. 
Previous studies have demonstrated that intensive reduction of cholesterol may be beneficial in the 
treatment
 of patients with isolated systolic hypertension [6]. The lipid and cholesterol lowering effects 
of prebiotics could be attributed to the production of short chain fatty acids (SCFA). It is commonly 
known that prebiotics resist digestion in the small intestine and reach the colon, where they are 
fermented by selective colonic microflora to produce SCFA such as acetate, propionate and lactate. 
The SCFA produced in the large bowel are absorbed in the portal vein, and
 a major part is metabolized 
by the liver and subsequently affects various metabolic processes [7]. Indigenous lactic acid bacteria 
and bifidobacteria often have the ability to ferment these indigestible prebiotics and produce lactate Int. J. Mol. Sci. 2009, 10                 
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and acetates as the main metabolites, with smaller amounts of propionate and butyrate. It has been 
reported that propionate could hinder
 fatty acid and cholesterol synthesis, while lactate produced in the 
colon plays a significant role in lowering the synthesis of triaclyglycerol fatty acids.  
Soluble prebiotics such as pectin, konjac mannan and modified starches are soluble in solutions 
leading to a thickening and viscous effect. Such physicochemical properties have been found to affect 
physiological responses such as the lowering of blood cholesterol, and increasing satiety by delaying 
gastric emptying and a reduced speed of gastric transit in the upper gastrointestinal tract. Levrat-Verny 
et al. [7] evaluated the hypocholesterolemic effects of soluble prebiotics such as guar gum and xanthan 
gum by using 56 male Wistar rats as a model. The authors found that the administration of 1% w/w of 
the individual prebiotics for three weeks resulted in increased bile acid flux in feces compared to the 
control, and a subsequent decrease in plasma and liver cholesterol contents. It was postulated that the 
soluble prebiotics inhibited intestinal cholesterol and bile absorption by increasing the viscosity
 of the 
digesta and the thickness of the unstirred layer in the
 small intestines.
 Other than soluble prebiotics, 
insoluble prebiotics have also been found to exert a hypocholesterolemic effect. They are not soluble, 
thus could shorten the time of gastric transit and increase the bulk of feces. It has been reported that 
these insoluble prebiotics could absorb fat and phospholipids in the lower intestines, leading to 
increased excretion in feces. Cholesterol levels have been reported to be reduced via the binding effect 
of prebiotics. Gallaher et al. [8] proposed that fiber could bind with bile
 acids and reduce solubilisation 
of cholesterol leading to a cholesterol lowering effect. The reduction of total cholesterol regulates the 
receptors of low density lipoprotein (LDL) and
 thus increases the clearance of LDL cholesterol [9]. 
This overall cholesterol lowering effect could reduce the stiffness of large arteries and thus could 
potentially reduce blood pressure [6].  
In another study, Lairon et al. [10] suggested that the reduction of obesity upon consumption of 
prebiotics such as fiber could prevent the elevation of blood pressure. Generally, overweighed and 
obese individuals are at a higher risk of hypertension than those with a healthy body mass index (BMI) 
[11]. Obesity has also been commonly associated with the overactivity of the sympathetic nervous 
system where long-term sympatho-activation could raise arterial pressure by
  causing peripheral 
vasoconstriction and by increasing renal
  tubular sodium reabsorption [11]. Therefore, decreasing 
obesity upon consumption of prebiotics could help to prevent or reduce the risk of hypertension. Past 
studies involving animals model mainly rats has shown promising evidence that ingestion of   
inulin-type fructans could regulate body weight via the promotion of endogenous glucagon-like 
peptide-1 (GLP-1) in the gut [12]. GLP-1 is a key hormone released from enteroendocrine-L cells
 in 
response to nutrient ingestion and is the key modulator of food intake by promoting satiety [13]. This 
consequently reduces the intake of food which leads to a decreased in body weight and BMI. Most of 
the studies involving the promotion of satiety by fructans via increased production of GLP-1 were 
performed in animal models and little information is available on human subjects. However, this 
remains a possible mechanism of fructans in promoting satiety. Piche et al. [14] had previously 
demonstrated that ingestion of 6.6 g of oligofructose three times a day for seven days increased the 
release GLP-1 in nine subjects. Although the GLP-1 level was not directly associated with satiety in 
this study, the promotion of GLP-1 in human was a plausible finding of the effects of fructans in 
human. In addition, it is interesting to note that ingestion of 16g/day of oligofructose for two weeks Int. J. Mol. Sci. 2009, 10                 
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decreased the total energy intake by 5% and increased satiety following breakfast and dinner in human 
subjects [15].  
Another possible mechanism by which prebiotics could regulate blood pressure includes the 
attenuation of insulin resistance [16]. Insulin resistance is a metabolic disorder and has been associated 
with impaired endothelium-dependent vasodilatation
  which could contribute to increased blood 
pressure [17]. Therefore, the alteration of insulin sensitivity could potentially protect against the 
development of this cardiovascular disease. Insoluble prebiotics have been found able to address this 
issue. Insoluble prebiotics are often extracted from native plant fibers such as cellulose, 
hemicelluloses, lignin and wheat bran. They have been found to improve postprandial glucose 
response and decreased secretion of insulin via a lowered glycemic index. The lower circulation of 
insulin up-regulates the insulin receptors and secondary signalling molecules resulting in increased 
tissue insulin sensitivity [18]. In addition, other insoluble prebiotics such as high cereal fiber has also 
been associated with the reduced risk of diabetes, mainly attributed to their metabolism in the
 colon by 
indigenous microflora producing SCFA and their effects on hepatic insulin sensitivity [19]. SCFA has 
been suggested to improve hepatic insulin sensitivity [20]. Cereal fiber also has a low glycemic index 
and has been studied for their roles in managing diabetes via lowering early postprandial 
hyperglycemia and
 decreasing risks of post-absorptive hypoglycemia [21]. 
Additionally, prebiotics have also been reported to reduce the risk of hypertension by improving the 
absorption of mineral such as calcium in the gastrointestinal tract [22]. Past studies have shown 
promising evidence on the correlation of dietary calcium and hypertension. Allender et al. [23] 
conducted a meta analysis of randomized clinical trials on the correlation of dietary calcium and blood 
pressure and had found that median
 intake of
 calcium by 1 g/day could significantly decrease the 
systolic blood pressure by 1 mm Hg to 2 mm
 Hg. Diets high in calcium have been found to reduce 
peripheral vascular resistance and blood pressure leading to a reduced risk of hypertension [24]. 
However, the beneficial effect of dietary calcium is dependent on its bioavailability and absorption in 
the intestinal lumen, and the absorption efficiency of calcium in human is low where only 25-30% of 
the calcium intake is being absorbed by the body [25]. The consumption of prebiotics such as inulin 
has been reported to enhance the absorption of calcium in human [26]. Prebiotics have been reported 
to increase the absorption of calcium via binding or sequestering calcium in the upper gastrointestinal 
tract. Bound or sequestered calcium on prebiotics would then reach the colon where it was being 
released from the prebiotics matrix and absorbed in the colon [27]. Therefore, the ingestion of 
prebiotics would increase the absorption of calcium and reduce the risk of hypertension. The 
absorption of calcium has also been found to increase in the presence of acids in the intestines [28]. 
Prebiotics are indigestible and thus escape digestion and serve as substrate to the microflora population 
in the lower intestines. SCFA and H
+ have been found to exchange for Ca
2+ in the distal colon regions 
[29]. This would then increase the concentration of Ca
2+ which favour passive diffusion and 
consequently absorbed by the human colon [27].  
 
3. In-Vivo Evidence of Antihypertensive Effects 
 
Numerous studies have positively indicated that the consumption of plant-derived prebiotics could 
exert a protective effect against hypertension. Direct association of prebiotics and antihypertension has Int. J. Mol. Sci. 2009, 10                 
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been established via various in-vivo trials (Table 1). However, hypertension is also highly associated 
with hypercholesterolemia and diabetes, where a lowering in cholesterol levels and improvement of 
glucose levels has been found to lower blood pressure. Prebiotics have been associated with the 
promotion of the overall well-being afflicted with blood glucose and blood lipid abnormalities   
(Table 2), while simultaneously exerting positive effect on blood pressure, thus reducing the risk 
factors of hypertension and coronary heart diseases. 
Table 1. Antihypertensive effects of plant derived prebiotics. 
Intervention  Experimental 
design  Subjects Dose  Effects  Ref 
Soluble fiber 
extracted from oat 
bran 
 
Randomized, 
double-blind, 
placebo-controlled  
 
n=110; 30 to 65 years; 
not on hypertension 
treatment; SBP of 
125-159 mmHg and 
DBP of < 95 mmHg 
8 g/d of fiber for 
12 weeks 
A reduction in 
SBP of 2.0 mmHg 
and DBP of 1.0 
mmHg  
 
[30] 
Diet containing soy 
protein isolate and 
supplementation of 
fiber extracted from 
psyllium  
Randomized, 
double-blind, 
parallel 
n=36; nonsmoking 
men or women > 20 
years old; on
 
antihypertensive drug 
therapy for > 6 
months; SBP of 130-
160 mmHg 
12 g fiber/d for 8 
weeks 
A reduction in 
SBP of 5.9 mmHg 
[31] 
Dietary fiber in the 
form of pill 
supplementation 
Randomized, 
double-blind, 
parallel, placebo-
controlled 
n=63; 18-70 yrs old; 
hypertensive with a 
minimum DBP of > 
90 mmHg  
7 g/d of dietary 
fiber for 12 
weeks 
A reduction in 
DBP of 5 mmHg 
[32] 
Beta-glucan from 
whole oats cereals 
Randomized, 
parallel, pilot trial 
n=18; 27-59 years old; 
healthy, untreated 
hypertensives with 
SBP of 130-160 
mmHg and DBP of 
85-100 mmHg 
5.52 g/d of beta-
glucan for 6 
weeks 
A reduction in 
SBP of 7.5 mmHg 
and DBP of 5.5 
mmHg  
[33] 
Bread substituted 
with lupin kernel 
flour 
Randomized,
 
parallel 
n=74; 20-70 years old; 
overweight and obese 
men and women with 
BMI of 25-35; 
SBP<150 mmHg and 
DBP<95 mmHg 
4 x 40g of 
bread/d for 16 
weeks; Bread 
contained 9.5% 
w/w of fiber 
A reduction in 
SBP of 3.0 mmHg 
[34] 
SBP: systolic blood pressure; DBP: diastolic blood pressure. 
Table 2. Effects of dietary fiber on blood glucose and lipid profiles. 
Intervention Fiber  Dose; duration 
of the study 
Experimental 
design  Animals/Subjects Effects  Ref 
Blood 
Glucose  
Alginate 
fiber 
5.0-g sodium 
alginate 
supplement 
(algaeisolate, 
75% soluble 
fiber); for two 
days 
Randomized, 
placebo-
controlled 
Seven men with type 
2 diabetes; mean age 
of 53 years 
Significantly reduced 
the postprandial rise in 
blood glucose 
(P<0.05) and in serum 
insulin (P<0.02) by 
31% and 42%, 
respectively 
[35]  
  Soy hulls  26 g of soy 
hulls which 
incorporated 
into 7 slices of 
bread daily; for 
4 weeks 
Randomized, 
double-blind, 
placebo-
controlled 
Ten subjects (5 male 
and 5 female) with 
type 2 diabetes; mean 
age of 65 ± 5.9 years 
Significantly 
improved the glucose 
score (P<0.05) and the 
total area under the 
glucose curve 
(P<0.05) by 6.7% and 
7.1%, respectively 
[36] Int. J. Mol. Sci. 2009, 10                 
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Table 2. Cont. 
Lipid Profile  Pectin  75 g citrus 
pectin daily; for 
four weeks 
Randomized, 
placebo-
controlled 
Six male adult 
hypercholesterolemic 
minipigs 
67.1% decrease in 
VLDL- cholesterol 
(P<0.05); 41.1% 
decrease in LDL-
cholesterol (P<0.05); 
49.4% decrease in 
total serum 
cholesterol (P<0.05) 
[37] 
 Fiber 
(Plantago 
ovata 
husk) 
10.5 g Plantago 
ovata husk 
daily; for eight 
weeks 
Randomized, 
crossover, 
placebo-
controlled, 
single-blind 
Twenty-eight men 
with myocardial 
infarction or stable 
angina 
6.7% decrease in 
plasma 
triacylglycerol 
(P<0.02), 6.7% 
increase in HDL-
cholesterol 
concentrations 
(P<0.006); 10.6% 
decrease in the total 
cholesterol/HDL 
ratio (P<0.002); 
14.2% decrease in 
LDL/HDL ratio 
(P<0.003) 
[38]  
 
3.1. Hypercholesterolemia 
 
In a study evaluating the influence of prebiotics on cholesterol, Mortensen et al. [39] administered a 
purified diet with 10% of long-chained fructan into male mice for 16 weeks. The control was not fed 
any prebiotics. The study involved 40 male mice and the results showed that the supplementation of 
fructan significantly reduced blood cholesterol by 29.7% (P<0.001), LDL-cholesterol concentration by 
25.9% (P<0.01), IDL-cholesterol level by 39.4% (P<0.001) and VLDL-cholesterol concentration by 
37.3% (P<0.05) compared to the control group.  
Davidson and Maki [40] conducted a randomized, double-blind, placebo-controlled and crossover 
design trial for 12 weeks involving 21 healthy volunteers to study the effect of prebiotic on lipid 
profiles. The authors found that the daily consumption of 18 g/day of inulin-supplemented foods 
significantly reduced plasma total cholesterol (P<0.02) and LDL-cholesterol (P<0.005) by 8.7%   
(± 3.3) and 14.4% (± 4.3), respectively compared to the control. In another study, Rault-Nania et al. 
[41] found that male Wistar rats fed with a diet containing inulin and oligofructose for 4 weeks showed 
a significant (P<0.05) decrease in hepatic triglycerides concentration as compared to those in the 
control group, whereby the blood pressure of those on inulin and oligofructose were in the range of 
138.0 ± 2.2 and 136.9 ± 2.0 mm Hg respectively, while the control showed a blood pressure of   
145.8 ± 1.3 mm Hg. 
Hypertriglyceridemia is often associated with a moderate hyperglycemia and insulinemia [42], and 
prebiotics have been found to reduce hepatic triacylglycerol. Daubioul et al. [43] administered 10 g of 
fructan to male mice for eight weeks. The study involved 16 male obese mice and the results showed 
that the fructan treatment significantly reduced (P<0.05) hepatic triacylgylcerol by 48% compared to 
the control group. In another study, Busserolles et al. [44] found that male Wistar-Han rats fed with a 
diet containing oligofructose for four weeks showed a significant (P<0.05) decline of 0.33% in hepatic 
triacylglycerol as compared to the control. These studies provided the experimental and clinical Int. J. Mol. Sci. 2009, 10                 
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evidence that the supplementation of prebiotics such as inulin and oligofructose could be used as a 
mean to control hypertension. 
 
3.2. Diabetes 
 
Experimental evidence has also demonstrated that diabetes elevates the risk of hypertension [45]. 
Dietary intervention is one of the main therapies proposed to diabetics, thus prebiotics have gained 
increasing attention because of their beneficial effects on lowering blood glucose. Therefore, prebiotics 
could act as antihypertensive agents upon the exhibition of blood glucose lowering effects. In a study 
evaluating the improvement of glucose tolerance via the intake of prebiotics, Cani et al. [46] 
administered an oligofructose-supplemented diet [10% (w/w)] to male mice for 14 weeks. The study 
used 32 male mice and the results showed that mice in the group consuming diet supplemented with 
oligofructose had improved glucose tolerance as compared to those in the control group. Mice on the 
oligofructose-supplemented diet showed normal fasting plasma insulin levels and restored glucose-
induced insulin secretion while the control did not. In another study, Frias and Sgarbieri [47] found 
that male Wistar rats (n=120) fed with diet containing 20% (w/w) of guar gum for 60 days showed a 
significantly (P<0.05) reduced serum glucose. Similarly, Kok et al. [48] studied the effects of 
oligofructose-enriched diet on glucose metabolism using rats as a model. The study involved 22 male 
Wistar rats that were fed a nonpurified diet and were randomly divided into two groups: those 
receiving nonpurified diet with 10% oligofructose (treatment group), or without oligofructose (control 
group) for 30 days. Throughout the 30-day treatment, the treatment group showed a significantly   
(P<0.05) reduced blood glucose by 26.0% as compared to those of the control group which only 
showed a reduction of 9.7%, which was insignificant statistically. The finding indicated that diet 
supplemented with oligofructose was effective in reducing blood glucose and indirectly could alleviate 
the risks of hypertension.  
Similarly, Suzuki and Hara [49] studied the effects of guar gum hydrolysate-enriched diet on 
glucose tolerance using rats as a model. The study used 31 male Sprague-Dawley rats that were fed a 
diet containing guar gum hydrolysate (75 g/kg) for 30 days. The treatment contributed to a significant 
(P<0.05) improvement of glucose intolerance as compared to the control. Giacco et al. [50] evaluated 
the effect of short-chain-fructooligosaccharides on glucose tolerance in 30 volunteers. The randomized, 
double-blind, placebo-controlled and crossover trial for two months showed that daily consumption of 
10 g/day of short-chain-fructooligosaccharides contributed to a significant (P<0.02) reduction of 
postprandial insulin response as compared to those in the placebo group which did not show any 
significant differences. 
Various studies have highlighted the beneficial effects of prebiotics on physiological conditions 
such as lipid and glucose profiles that are directly associated with hypertension. Hence, there is a 
strong basis for continuous evaluation on prebiotics specifically aimed at utilizing longer and larger  
in-vivo trials.  
 Int. J. Mol. Sci. 2009, 10                 
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4. Controversial Studies 
 
Epidemiological studies have found that hypertensive patients frequently have a high level of serum 
cholesterol. Blood pressure and cholesterol are closely related and many researches have demonstrated 
that the lowering of cholesterol contributes to antihypertension effects. Thus, an increase in both serum 
cholesterol and triglycerides had been reported to elevate blood pressure values [51]. According to 
Boyd et al. [52] and Ferrara et al. [51], blood pressure elevated with a higher prevalence of low  
HDL-cholesterol and high LDL-cholesterol levels while mildly increased serum cholesterol levels are 
able to influence hypertension. Although increasing uptake of prebiotics have been reported to reduce 
plasma lipid levels, controversies are raised where a number of studies have reported otherwise.  
According to Luo et al. [53], blood lipids in twelve healthy volunteers were not affected by the 
consumption of nondigestible oligosaccharides (NDO) such as short-chain fructooligosaccharides 
(FOS). The consumption of FOS enriched cookies (20 g/day) in a double-blind randomized crossover 
design over 4 weeks showed that serum triacylglycerol, total- and HDL cholesterol, apoliprotein A-I 
and B and lipoprotein concentrations remained relatively constant and did not differ compared to the 
control. In another randomized, double-blind and diet-controlled study involving twelve healthy men, 
Van Dokkum et al. [54] showed that the cholesterol lowering effect of NDO was insignificant. The 
incorporation of inulin, FOS and galacto-oligosaccharides (GOS) in food products in quantities up to 
15 g/day did not exhibit a reduction in blood lipid profiles. Although factors such as healthy subjects 
and low concentrations of initial serum cholesterol could affect the outcomes of these studies, the 
results showed that NDO may not possess antihypertensive effects.  
In another study, Pedersen et al. [55] reported that the daily intake of 14 g of inulin added to a low 
fat spread in the diet of sixty-four healthy young females in a randomized double-blind crossover study 
involving two periods of four weeks did not affect the concentrations of triacylglycerols, HDL and 
LDL-cholesterol. There was insignificant difference in blood lipids between the placebo and treatment 
group. Ellegard et al. [56] also showed similar findings. In a double-blind crossover study, the 
consumption of 16-17 g/d of inulin and FOS in a controlled diet by ten subjects with conventional 
ileostomy did not show significant effects on absorption and excretion of cholesterol. In another study 
by Williams [57], fifty-eight middle-aged hypercholesterolemic subjects consuming 10 g/day of inulin 
showed insignificant changes in total, LDL or HDL-cholesterol or apolipoproteins B and A over   
eight weeks.  
Jenkins et al. [58] used a crossover design involving eight healthy subjects and showed that daily 
ingestion of 18-25 g/day of lactulose in dissolved water over two weeks not only did not reduce lipid 
concentrations but raised the fasting serum total- and LDL-cholesterol and apoliprotein B 
concentrations. The authors reported that the failure of lactulose to lower serum lipids may related to 
inadequate generation of propionate and predominant of acetate short chain fatty acids (SCFA) 
because six of the eight subjects showed higher serum acetate concentrations. In another animal study 
involving rats as a model also showed a significant rise in liver cholesterol concentrations after four 
weeks of dietary supplementation with lactulose [59]. Fermentable dietary fibers such as prebiotics 
escape digestion in small intestine and are fermented in the cecum and colon, producing SCFA mainly 
acetate, propionate and butyrate [60]. According to Beynen et al. [61], acetate is a precursor of 
cholesterol synthesis and it has been shown to enhance lipogenesis in rat hepatocytes.  Int. J. Mol. Sci. 2009, 10                 
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The concordance of hypertension and diabetes is increased in the population and hypertension is 
disproportionately higher in diabetics [62]. High blood glucose levels in hyperglycemia patients are 
more likely to elevate blood pressure [63]. Although prebiotics have been widely reported to improve 
blood glucose profiles, some studies have also suggested otherwise. Alles et al. [64] previously used a 
randomized, single-blind, placebo-controlled and crossover design involving twenty patients with type 
2 diabetes. The authors reported that the supplementation of FOS (15 g/d) for 20 days did not 
significantly affect blood glucose concentrations in patients with type 2 diabetes. Luo et al. [65] also 
showed similar findings in a trial involving ten type 2 diabetic volunteers. These subjects received  
20 g/d FOS for four weeks in a double-blind crossover design. The authors found that FOS did not 
modify plasma glucose and insulin concentrations or basal hepatic glucose production. The authors 
attributed the absence of glucose lowering effect of FOS to the relatively small doses used in the 
subjects. In a randomized, single-blind and crossover study involving eighteen mildly hyperlipidemic 
subjects, Keogh et al. [66] demonstrated that the administration of β-glucan enriched barley for two 
period of four weeks did not significantly change blood glucose levels. In another study, McIntosh  
et al. [67] evaluated the effect of blood glucose upon the consumption of dietary fiber in a crossover 
trial involving twenty-one mildly hypercholesterolemic subjects. The authors found that the daily 
intake of 21-38 g of barley foods containing β-glucan and wheat containing cellulose and 
hemicelluloses fiber for four weeks did not alter the concentrations of blood glucose.  
Future studies aimed at investigating the effects of prebiotics on serum cholesterol or blood glucose 
concentration should consider the choice of subjects and the length of the supplementation period. Past 
studies investigating on the effects of NDO such as inulin and FOS in humans on hypertension remains 
relatively controversial. However, considering the vast experimental evidence on their positive roles, 
the potential of prebiotics as an antihypertensive agents warrant further investigations. 
 
5. Conclusions 
 
Results from recent studies support the antihypertensive potential of plant-based prebiotics, and 
shown that they could exert such a beneficial effect via various mechanisms. Although controversial 
findings are raised, positive outcomes from both in-vitro experiments and in-vivo trials have exhibited 
the need for further evaluation of the antihypertensive properties of plant-based prebiotics.  
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